Latest Synageva Biopharma Corp (GEVA) Headlines
Insider Trading Alert - BID, FMER And GEVA Traded By Insiders
at The Street - Mon Mar 10, 1:00PM CDT
Stocks with insider trader activity include BID, FMER and GEVA
Synageva Biopharma prices public offering at USD105.75 per share
M2 - Thu Mar 06, 4:41AM CST
US-based biopharmaceutical company Synageva BioPharma (NasdaqGS:GEVA) said on Wednesday that it has priced its public offering of 2.0m common shares at USD105.75 per share.
Synageva Biopharma Announces Pricing of Public Offering of Common Stock
Business Wire - Wed Mar 05, 4:37PM CST
Synageva BioPharma Corp. ("Synageva") (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced the pricing of its previously announced underwritten public offering of common stock consisting of 2.0 million shares at $105.75 per share. In connection with this offering, Synageva granted to the underwriters a 30-day option to purchase 300,000 additional shares of common stock. If the underwriters exercise this option, Synageva will have offered 2.30 million shares of its common stock.
Appointments, Earnings Results, Drug Applications, Conferences, and Approvals - Analyst Noteson Boston Scientific, Covidien, St. Jude Medical, Synageva BioPharma, and Ligand Pharmaceuticals
PR Newswire - Wed Mar 05, 3:00PM CST
Editor Note: For more information about this release, please scroll to bottom.
Synageva Biopharma to offer 2m common shares in public offering
M2 - Wed Mar 05, 5:34AM CST
US-based biopharmaceutical company Synageva BioPharma (NasdaqGS:GEVA) said on Tuesday that it plans to issue 2m shares of its common stock in an underwritten public offering.
Synageva Biopharma(TM) Announces a 2.00 Million Share Proposed Public Offering of Its Common Stock
Business Wire - Tue Mar 04, 3:31PM CST
Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced that it intends to offer for sale 2.00 million shares of its common stock in an underwritten public offering. In connection with this offering, Synageva expects to grant to the underwriters a 30-day option to purchase up to an additional 300,000 shares of its common stock. If the underwriters exercise this option, Synageva will have offered 2.30 million shares of its common stock. Goldman, Sachs & Co., J.P. Morgan Securities LLC, and Morgan Stanley & Co. LLC are serving as book-running managers for the offering.
Why Synageva BioPharma Corp. Shares Briefly Surged
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 04, 12:43PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Synageva BioPharma , a clinical-stage...
Synageva 4Q Loss Narrower-than-Expected Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 10:00AM CST
Synageva BioPharma Corp. (GEVA) reported fourth quarter 2013 loss of $1 per share, wider than the year-ago loss of 62 cents per share, but narrower than the Zacks Consensus Estimate of a loss of $1.02 per share.
Concise Analysis of the International Bolus Injectors Market, 2014 - 2024
M2 - Tue Mar 04, 6:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/jpbd3g/bolus_injectors) has announced the addition of the "Concise Analysis of the International Bolus Injectors Market, 2014 - 2024" report to their offering. The injectable drug delivery market holds significant potential for the future. From conventional syringes with vials and painful needles to the modern-day pre-filled syringes, pen-injectors, needle free injectors and auto-injectors, the injectable drug delivery devices market has come a long way. Taking the concept of self-injectors to a new stratum, Bolus Injectors' have surfaced recently. Also known as non-insulin patch pumps, these devices not only offer a range of benefits to the end users but also provide a number of additional benefits to other stakeholders in the industry. One of the main drivers for the perceived growth of bolus injectors is the large number of biologics currently under development. A majority of these molecules are highly viscous and are required to be delivered in volumes of greater than 1 ml. The absence of devices which can safely administer these drugs is currently a big unmet need in the market. However, the early signs are encouraging. Despite the uncertainties related to the device development and approval, many companies are investing time, money and resources to develop novel devices. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Overview And Market Background 4. Target Drugs For Bolus Injectors 5. Product Profiles 6. Market Size And Forecast 7. Swot Analysis 8. Company Profiles 9. Interview Transcripts 10. Conclusion 11. Appendix 1: Tables 12. Appendix 2: List Of Companies Companies Mentioned: - AbbVie - Abbott - BMS - Boehringer Ingelheim - Calando Pharmaceuticals - Calibra Medical - Dekkun - Denderon - Eisai - Elcam Medical - Eli Lilly - Five Prime Therapeutics - Future Injection Technologies - Genentech - Genethon - Isis Pharmaceuticals - J&J - Janssen Biotech - Kyowa Hakko Kirin - Lincoln Medical Limited - MacroGenics - Nuron Biotech - Octapharma - OncoGenex Technologies - Pfizer - PhaseBio Pharmaceuticals - Roche - SteadyMed Therapeutics - Synageva BioPharma - TaiMed Biologics - Takeda Pharmaceuticals - VBL Therapeutics - West Pharmaceutical Services - Xbiotech - Ypsomed - ZZ Biotech For more information visit http://www.researchandmarkets.com/research/jp..._injectors
Synageva BioPharma(TM) Issued U.S. Patent for Treatment of LAL Deficiency
Business Wire - Tue Mar 04, 6:05AM CST
Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, announced that the U.S. Patent and Trademark Office today issued U.S. Patent No. 8,663,631 covering methods of treating lysosomal acid lipase deficiency (LAL Deficiency). This patent provides protection until 2031, not including any patent term extension. The patent complements Synageva's existing and planned global patent portfolio covering its LAL Deficiency program, which includes intellectual property directed to composition of matter, methods of use, and manufacturing.
Nasdaq stocks posting largest percentage decreases
AP - Mon Mar 03, 5:05PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Synageva BioPharma(TM) Reports 2013 Full Year Financial Results
Business Wire - Mon Mar 03, 3:05PM CST
Synageva BioPharma Corp. ("Synageva") (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today reported 2013 full year financial results and provided 2014 goals, other key objectives, and financial guidance. Synageva's management team will host a conference call today at 4:30 p.m. EST to review the financial results and provide a general business update. To participate in today's call by telephone, please dial (877) 445-4603 for U.S. callers or (443) 295-9270 for international callers. In addition, the conference call will be webcast live from the "Webcasts & Presentations" section of the Investor Relations tab on the home page of Synageva's website at www.synageva.com.
Synageva BioPharma(TM) Joins NORD, EURORDIS, and The Global Genes Project in Support of Rare Disease Day 2014
Business Wire - Fri Feb 28, 6:55AM CST
Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, joins the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORDIS), The Global Genes Project, and others around the world in observing Rare Disease Day.
3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed Feb 26, 3:35PM CST
I follow quite a lot of companies, so the usefulness of a watchlist for me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...
Synageva BioPharma(TM) to Present at the Cowen and Company Health Care Conference
Business Wire - Fri Feb 21, 9:00AM CST
Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, today announced its presentation at the upcoming Cowen and Company 34th Annual Health Care Conference being held in Boston, MA.
Synageva BioPharma Corp. (GEVA) in Focus: Stock Moves 5.1% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 8:21AM CST
Synageva BioPharma Corp. (GEVA) was a big mover last session, as the company saw its shares rise by over 5% on the day.
Synageva BioPharma Corp.Corporate Event Announcement Notice
Wall Street Horizon - Wed Feb 19, 8:02PM CST
The following issues have been halted by IIROC:
Synageva BioPharma(TM) to Host 2013 Fourth Quarter and Full Year Financial Results Conference Call on March 3
Business Wire - Tue Feb 18, 12:16PM CST
Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, will report 2013 fourth quarter and full year financial results after the NASDAQ Market closes on Monday, March 3, 2014. Synageva management will conduct a conference call and audio webcast to discuss these results as well as provide a general business update at 4:30 p.m. EST on the same day.
Intercept Expands Its Board of Directors With Appointments of Sanj K. Patel and Glenn Sblendorio
GlobeNewswire - Tue Feb 18, 5:50AM CST
Intercept Pharmaceuticals, Inc. (Intercept or the Company) (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases, today announced the appointment of Sanj K. Patel and Glenn Sblendorio to the Company's Board of Directors, effective immediately. Patel is currently the President and Chief Executive Officer of Synageva Biopharma Corp. (Nasdaq:GEVA) and Sblendorio is the President and Chief Financial Officer of The Medicines Company (Nasdaq:MDCO). With these additions, Intercept's Board of Directors is now comprised of nine directors.
Insider Trading Alert - BID, FMER And GEVA Traded By Insiders
at The Street - Mon Mar 10, 1:00PM CDT
Stocks with insider trader activity include BID, FMER and GEVA
Synageva Biopharma prices public offering at USD105.75 per share
M2 - Thu Mar 06, 4:41AM CST
US-based biopharmaceutical company Synageva BioPharma (NasdaqGS:GEVA) said on Wednesday that it has priced its public offering of 2.0m common shares at USD105.75 per share.
Synageva Biopharma Announces Pricing of Public Offering of Common Stock
Business Wire - Wed Mar 05, 4:37PM CST
Synageva BioPharma Corp. ("Synageva") (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced the pricing of its previously announced underwritten public offering of common stock consisting of 2.0 million shares at $105.75 per share. In connection with this offering, Synageva granted to the underwriters a 30-day option to purchase 300,000 additional shares of common stock. If the underwriters exercise this option, Synageva will have offered 2.30 million shares of its common stock.
Appointments, Earnings Results, Drug Applications, Conferences, and Approvals - Analyst Noteson Boston Scientific, Covidien, St. Jude Medical, Synageva BioPharma, and Ligand Pharmaceuticals
PR Newswire - Wed Mar 05, 3:00PM CST
Editor Note: For more information about this release, please scroll to bottom.
Synageva Biopharma to offer 2m common shares in public offering
M2 - Wed Mar 05, 5:34AM CST
US-based biopharmaceutical company Synageva BioPharma (NasdaqGS:GEVA) said on Tuesday that it plans to issue 2m shares of its common stock in an underwritten public offering.
Synageva Biopharma(TM) Announces a 2.00 Million Share Proposed Public Offering of Its Common Stock
Business Wire - Tue Mar 04, 3:31PM CST
Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced that it intends to offer for sale 2.00 million shares of its common stock in an underwritten public offering. In connection with this offering, Synageva expects to grant to the underwriters a 30-day option to purchase up to an additional 300,000 shares of its common stock. If the underwriters exercise this option, Synageva will have offered 2.30 million shares of its common stock. Goldman, Sachs & Co., J.P. Morgan Securities LLC, and Morgan Stanley & Co. LLC are serving as book-running managers for the offering.
Why Synageva BioPharma Corp. Shares Briefly Surged
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 04, 12:43PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Synageva BioPharma , a clinical-stage...
Synageva 4Q Loss Narrower-than-Expected Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 10:00AM CST
Synageva BioPharma Corp. (GEVA) reported fourth quarter 2013 loss of $1 per share, wider than the year-ago loss of 62 cents per share, but narrower than the Zacks Consensus Estimate of a loss of $1.02 per share.
Concise Analysis of the International Bolus Injectors Market, 2014 - 2024
M2 - Tue Mar 04, 6:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/jpbd3g/bolus_injectors) has announced the addition of the "Concise Analysis of the International Bolus Injectors Market, 2014 - 2024" report to their offering. The injectable drug delivery market holds significant potential for the future. From conventional syringes with vials and painful needles to the modern-day pre-filled syringes, pen-injectors, needle free injectors and auto-injectors, the injectable drug delivery devices market has come a long way. Taking the concept of self-injectors to a new stratum, Bolus Injectors' have surfaced recently. Also known as non-insulin patch pumps, these devices not only offer a range of benefits to the end users but also provide a number of additional benefits to other stakeholders in the industry. One of the main drivers for the perceived growth of bolus injectors is the large number of biologics currently under development. A majority of these molecules are highly viscous and are required to be delivered in volumes of greater than 1 ml. The absence of devices which can safely administer these drugs is currently a big unmet need in the market. However, the early signs are encouraging. Despite the uncertainties related to the device development and approval, many companies are investing time, money and resources to develop novel devices. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Overview And Market Background 4. Target Drugs For Bolus Injectors 5. Product Profiles 6. Market Size And Forecast 7. Swot Analysis 8. Company Profiles 9. Interview Transcripts 10. Conclusion 11. Appendix 1: Tables 12. Appendix 2: List Of Companies Companies Mentioned: - AbbVie - Abbott - BMS - Boehringer Ingelheim - Calando Pharmaceuticals - Calibra Medical - Dekkun - Denderon - Eisai - Elcam Medical - Eli Lilly - Five Prime Therapeutics - Future Injection Technologies - Genentech - Genethon - Isis Pharmaceuticals - J&J - Janssen Biotech - Kyowa Hakko Kirin - Lincoln Medical Limited - MacroGenics - Nuron Biotech - Octapharma - OncoGenex Technologies - Pfizer - PhaseBio Pharmaceuticals - Roche - SteadyMed Therapeutics - Synageva BioPharma - TaiMed Biologics - Takeda Pharmaceuticals - VBL Therapeutics - West Pharmaceutical Services - Xbiotech - Ypsomed - ZZ Biotech For more information visit http://www.researchandmarkets.com/research/jp..._injectors
Synageva BioPharma(TM) Issued U.S. Patent for Treatment of LAL Deficiency
Business Wire - Tue Mar 04, 6:05AM CST
Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, announced that the U.S. Patent and Trademark Office today issued U.S. Patent No. 8,663,631 covering methods of treating lysosomal acid lipase deficiency (LAL Deficiency). This patent provides protection until 2031, not including any patent term extension. The patent complements Synageva's existing and planned global patent portfolio covering its LAL Deficiency program, which includes intellectual property directed to composition of matter, methods of use, and manufacturing.
Nasdaq stocks posting largest percentage decreases
AP - Mon Mar 03, 5:05PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Synageva BioPharma(TM) Reports 2013 Full Year Financial Results
Business Wire - Mon Mar 03, 3:05PM CST
Synageva BioPharma Corp. ("Synageva") (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today reported 2013 full year financial results and provided 2014 goals, other key objectives, and financial guidance. Synageva's management team will host a conference call today at 4:30 p.m. EST to review the financial results and provide a general business update. To participate in today's call by telephone, please dial (877) 445-4603 for U.S. callers or (443) 295-9270 for international callers. In addition, the conference call will be webcast live from the "Webcasts & Presentations" section of the Investor Relations tab on the home page of Synageva's website at www.synageva.com.
Synageva BioPharma(TM) Joins NORD, EURORDIS, and The Global Genes Project in Support of Rare Disease Day 2014
Business Wire - Fri Feb 28, 6:55AM CST
Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, joins the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORDIS), The Global Genes Project, and others around the world in observing Rare Disease Day.
3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed Feb 26, 3:35PM CST
I follow quite a lot of companies, so the usefulness of a watchlist for me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...
Synageva BioPharma(TM) to Present at the Cowen and Company Health Care Conference
Business Wire - Fri Feb 21, 9:00AM CST
Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, today announced its presentation at the upcoming Cowen and Company 34th Annual Health Care Conference being held in Boston, MA.
Synageva BioPharma Corp. (GEVA) in Focus: Stock Moves 5.1% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 8:21AM CST
Synageva BioPharma Corp. (GEVA) was a big mover last session, as the company saw its shares rise by over 5% on the day.
Synageva BioPharma Corp.Corporate Event Announcement Notice
Wall Street Horizon - Wed Feb 19, 8:02PM CST
The following issues have been halted by IIROC:
Synageva BioPharma(TM) to Host 2013 Fourth Quarter and Full Year Financial Results Conference Call on March 3
Business Wire - Tue Feb 18, 12:16PM CST
Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, will report 2013 fourth quarter and full year financial results after the NASDAQ Market closes on Monday, March 3, 2014. Synageva management will conduct a conference call and audio webcast to discuss these results as well as provide a general business update at 4:30 p.m. EST on the same day.
Intercept Expands Its Board of Directors With Appointments of Sanj K. Patel and Glenn Sblendorio
GlobeNewswire - Tue Feb 18, 5:50AM CST
Intercept Pharmaceuticals, Inc. (Intercept or the Company) (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases, today announced the appointment of Sanj K. Patel and Glenn Sblendorio to the Company's Board of Directors, effective immediately. Patel is currently the President and Chief Executive Officer of Synageva Biopharma Corp. (Nasdaq:GEVA) and Sblendorio is the President and Chief Financial Officer of The Medicines Company (Nasdaq:MDCO). With these additions, Intercept's Board of Directors is now comprised of nine directors.
